相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商:
齐源
- 库存:
999
- 靶点:
CD369
- 级别:
CD369 (Dectin-1/CLEC7A) Antibody
- 目录编号:
CD369 (Dectin-1/CLEC7A) Antibody
- 克隆性:
单克隆
- 抗原来源:
小鼠
- 保质期:
CD369 (Dectin-1/CLEC7A) Antibody
- 抗体英文名:
Purified anti-human CD369 (Dectin-1/CLEC7A) Antibody
- 抗体名:
CD369 (Dectin-1/CLEC7A) Antibody
- 标记物:
CD369 (Dectin-1/CLEC7A) Antibody
- 宿主:
小鼠
- 适应物种:
人
- 免疫原:
CD369 (Dectin-1/CLEC7A) Antibody
- 亚型:
CD369 (Dectin-1/CLEC7A) Antibody
- 形态:
CD369 (Dectin-1/CLEC7A) Antibody
- 应用范围:
FC, IHC-F
- 保存条件:
2-8℃
- 浓度:
0.5 mg/ml
- 规格:
100 µg
Description :CD369 (Dectin-1), also known as CLEC7A and beta-glucan receptor (BGR), is a 33 kD type IItransmembrane C-type lectin. It consists of a C-terminal stalk with a carbohydrate recognitiondomain (CRD) in the extracellular domain, a transmembrane segment, and a short N-terminalITAM containing a cytoplasmic tail. CLEC7A is predominantly expressed on dendritic cells.Subsequent work has shown expression on B cells, monocytes, eosinophils, mast cells,macrophages, endothelial cells, and low expression on some subsets of T cells. CLEC7A lacksresidues involved in calcium ligation that mediates carbohydrate-binding by classical C-typelectins. CLEC7A functions as a receptor to mediate innate immunity to fungal pathogens byselectively binding beta-glucan polymers, a major component of yeast and mycobacterial cellwalls.
Verified Reactivity :Human
Antibody Type :Monoclonal
Host Species :Mouse
Immunogen :Ectodomain with C-term hFc fusion, RIBLS.
Formulation :Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation :The antibody was purified by affinity chromatography.
Concentration :0.5 mg/ml
Storage & Handling :The antibody solution should be stored undiluted between 2°C and 8°C.
Application :FC - Quality tested、IHC-F - Reported in the literature, not verified in house
Recommended Usage :Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验1. Ni L, et al. 2010. J. Immunol. 185:3504. (IHC)
Product Citations:
1. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
2. Sander J et al. 2017. Immunity. 47(6):1051-1066 . PubMed
无反应状态或死亡。 在体外联合使用 CD3 和 CD28 的抗体刺激 T 细胞,模拟 T 细胞活化的双信号作用,是进行 T 细胞激活与扩增应用最广泛的方法。除直接使用功能学抗体以外,目前磁珠法(CD3/CD28 抗体偶联磁珠)以及多聚体法(CD3/CD28 抗体偶联 Streptamer 多聚体)也是激活扩增 T 细胞比较常见的两种方法。以上说到的无论是抗体法、磁珠法、亦或者是多聚体法,归根结底都是借助于 CD3 与 CD28 抗体对 T 细胞进行刺激。 下面,我们以小鼠脾脏样本为例,分享
CD11a/CD11b/CD11c 分子 CDlla 常用单克隆抗体或代号:MHM24, 2F12; CRIS―3(LFA―lα链,整合素α1) 主要表达细胞:Leu[A5] 分子质量(kDa)和结构:spl80(整合素α) 功 能:与1CAM-l(CD54)、ICAM-2(CDl02)、ICAM-3(C1350)结合,介导细胞黏附;与JAMl结合,参与白细胞穿过内皮细胞
临床验证。抗人CD20(Rituximab)是第1个为FDA批准可用于临床癌症治疗的单抗。Rituximab与细胞表面的CD20分子结合后,可通过诱导ADCC和CDC清除高表达CD20分子的恶性B细胞,从而被认为在低分化的B细胞淋巴瘤和非霍奇金淋巴瘤的治疗中起重要作用。 近年来,另一个备受人们关注的治疗性单抗是抗Her-2的抗体。Her-2是表皮生长因子受体(EGFR)成员,参与乳腺癌的发生,且与乳腺癌患者的预后有关。相应单抗与Her-2结合可阻止Her-2与相应的生长因子的结合,抑制乳腺










